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Abstract 
This paper has three aims: first, to examine what impact certain macroeconomic 
and health-related factors would have on the financial sustainability of health 
care systems; second, to provide insights as to the additional financial resources 
that may be needed over the next few years in order for such demand to be met 
and for health systems not to register a funding gap; and, third, to reflect on the 
evidence presented on the previous objectives and offer an agenda for reform 
and action by health care decision makers. 
Data from eight OECD countries on macroeconomic (GDP growth, fiscal deficit, 
overall debt), demographic and health-related indicators and spending was 
retrieved from publically available data sources (OECD and the IMF) and 
national statistics in order to ascertain the performance over time of key 
variables influencing health spending. Using ordinary least squares regression 
analysis and taking into account historical health spending growth patterns and 
the increasing demand for health care, the future levels of health spending are 
calculated (2013-2020) and benchmarked against a baseline scenario of zero 
growth in real health care spending over the period from 2013-2020.  
It is shown that GDP growth is declining over the long term in most countries 
and that in all eight countries public debt levels have been increasing steadily 
over the past decades with increasing fiscal deficits and debt levels between 
2000 and 2010. The ratio of economically active to retired population is 
decreasing in all countries, gradually shrinking the revenue base for health and 
other public spending. Public pension spending has plateaued between 2000 and 
2010, with reductions observed in Spain, Germany and Poland partly as a result 
of reforms undertaken by governments. In contrast, the expenditure on health 
care is rising monotonously, accelerating in some countries (UK, Spain, Poland 
and Canada) and decelerating in others (Italy, Germany, Australia, France). 
Spending on pharmaceuticals is also rising though this growth has slowed in the 
past decade across all countries. Assuming revenues for health care are fixed at 
2012 levels, the funding shortfall in 2017 may range between 12% (optimistic 
case) and 18% (pessimistic case) of 2012 health expenditure levels. The 
cumulative 5 year shortfall is likely to range between 39.4% (optimistic) and 61% 
(pessimistic) of 2012 health expenditure levels. 
The combination of current and future austerity measures, a declining 
economically active population and greater difficulties in financing public deficits 
with debt may result in a financial squeeze of the health care sector while 
demand for services and uptake of new technologies and treatments continues to 
grow. Health care decision makers will – among other things - need to place 
emphasis on outcomes-based reimbursement, prioritise based on efficiency rules 
in order to ensure affordability, and implement organizational innovations. 
Unless these are adhered to, it is likely that exclusions from coverage will be the 
net result. 
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1. INTRODUCTION 
In recent decades, spending on publicly funded health systems has risen at a 
higher rate than overall economic growth. From 1970 to the early 1980s, 
average public spending as a proportion of gross domestic product (GDP) 
increased by 50% among member states of the Organization for Economic Co-
operation and Development (OECD). Even in countries that have been successful 
at containing health expenditure, such as Sweden, GDP growth was still outpaced 
by health expenditure growth by a factor of 1.45 between 1970 and 2000, while 
the same figure for the United States of America (USA) was 2.01.  
In the absence of additional policy measures, health spending in OECD countries 
was projected to increase from an average of 5.7% of GDP in 2005 to 9.6% in 
2050. Long term care costs are projected to treble from 1.1% to 3.3% of GDP 
over the same period (Martins and De la Maisonneuve, 2006). In the wake of one 
of the most severe financial crises in recent history, where many governments 
slashed public spending to reduce budget deficits, resources for health and social 
care were also affected (Stuckler et al., 2010) including countries such as the USA, 
where health spending drives a significant proportion of public debt (Chernew et 
al., 2010), but also more generally in European countries facing significant fiscal, 
external1 and other macroeconomic imbalances (Sinn, 2012). Together these 
factors warrant a closer look at the drivers of health care expenditure and the 
identification of policy levers to mitigate uncontrolled growth in health spending 
while preserving the core values of national health systems including equity, 
universal coverage and intergenerational solidarity. 
Principles and priorities for health systems have in the vast majority of cases 
featured effectiveness, cost-effectiveness and necessity, but the issue of financial 
sustainability has not been addressed (Kenny and Joffres, 2008) until recently, 
possibly because the combination of an ageing baby-boom generation and 
continuing innovation in healthcare technology only now poses the 
unprecedented challenge of having to provide more services for less available 
resource. It has nevertheless come to the fore in recent years because of the 
financial crisis (Thomson et al., 2014). 
The long-term financial sustainability of national health systems now depends on 
the ability of decision makers to balance the challenges of what seems to be a 
very arduous environment: a higher proportion of elderly people relative to 
those in working age, higher demand for health care from an increasingly well-
informed public, more expensive technological innovations, and greater pressure 
on other social care budgets (e.g. pensions, rising prices, less contributors to pay 
for everything and severe restrictions on the ability of governments to run up 
deficits to plug funding gaps).  
                                                                    
1 As they relate to transactions of a country with the rest of the world. 
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In light of the above, the objective of this paper is threefold: first, to examine 
what impact certain macroeconomic and health-related factors would have on 
the financial sustainability of health care systems; second, based on current 
levels of demand for health care and responding to financial challenges, to 
provide insights as to the additional financial resources that may be needed over 
the next few years in order for such demand to be met and for health systems not 
to register a funding gap; and, third, to reflect on the evidence presented on the 
previous objectives and offer an agenda for reform and action by health care 
decision makers. 
 
2. METHOD AND ORGANISATION OF THE PAPER 
2.1 DATA SOURCES AND DEFINITIONS 
In order to fulfil the paper’s objectives we use data from publicly available 
sources.  Such data include macroeconomic indicators (e.g. fiscal deficit, 
gross/net debt, GDP, public pensions), demographic indicators (e.g. life 
expectancy, share of people over 65 in the total population), health and 
pharmaceutical related expenditures and utilization.  
Data on fiscal deficit (“General government net lending/borrowing”), and 
gross/net debt (“General government net/gross debt”) were retrieved from the 
International Monetary Fund (IMF) World Economic Outlook database (IMF, 
2014b). Data on GDP, public pensions, life expectancy, elderly population, 
pharmaceutical expenditure and total health expenditure were retrieved from 
the Organisation for Economic Co-operation and Development (OECD) Statistics 
database (OECD, 2014b). Old age support (dependency) ratio data, including 
projections, were extracted from “Pensions at a Glance 2013”(OECD, 2013). 
Pharmaceutical expenditure as a percentage of total health expenditure 
(pharmaceutical and other non-durables, % current expenditure on health) was 
retrieved from “OECD Health Data 2014” (OECD, 2014a). For comparability, 
national currency units (NCUs) were converted to euros (€) using average 
annual exchange rates from the IMF International Financial Statistics database 
(IMF, 2014a).  
Health care expenditure is classified according to the System of Health Accounts 
(OECD, 2014b; OECD/EUROSTAT/WHO, 2011; OECD, 2015 p. 1). The “Total 
health expenditure” category includes: financing agents, functions (e.g. curative 
care, long-term care, preventive care, among others), providers, and financing 
sources. Gross Domestic Product (GDP, Output Approach) and all expenditure 
categories when expressed in national currency units (NCUs) were deflated 
using the World Bank year-on-year GDP deflator using as a base year 1990 
(WorldBank, 2014). Old age support ratio (dependency ratio) is defined as the 
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number of population aged 20-64 years old divided by the number of population 
65 or older (OECD, 2014b).  
Countries included in the analysis were selected to represent a sample of 
predominantly tax- (UK, Spain, Poland), social health insurance (France, 
Germany) and mixed (Australia, Canada, Italy) health care systems (Table 1). 
 
2.2 OBJECTIVES, ASSUMPTIONS AND PROJECTIONS 
The first objective of the paper is to examine the extent to which certain 
exogenous and endogenous factors impact on the financial sustainability of 
health care systems in the study countries. This was done by examining a 
number of contributions from the literature. In so doing, section 3 of the paper 
examines the importance of demographic developments, the need for public 
pension reform, the impact of ageing, the rising impact of long-term care 
arrangements, the impact of technological development and the responses by 
many health care systems in terms of cost containment measures and efforts to 
improve efficiency in the provision of services. 
The second objective of the paper is to provide insights as to the additional 
financial resources that may be needed over the next few years in order for such 
demand to be met and for health systems not to register a funding gap.  We 
proceed by identifying key exogenous factors (acting independently of the 
healthcare system but may still have a major influence on system performance 
and sustainability, for example key macroeconomic variables) and endogenous 
factors (those influencing expenditure directly). We subsequently examine 
current and earlier trends over the 1980 – 2012 period to assess how their 
performance over time and in light of recent developments is likely to influence 
the direction of demand for health care and the ability of expenditure to respond 
to it in the near future. We then undertake projections of health care 
expenditures in order to determine whether demand for health will outstrip 
potentially available resources, in which case there would be a funding gap. 
These future projections were based on linear regression models using ordinary 
least squares and relying on information and data over the 1990 – 2010 period. 
For the cases of variables such as male life expectancy at 65 and the proportion 
of the over-65s in the population, projections were made using annual data and 
for the 10 most recent years. Future projections on old age dependency ratios 
and macroeconomic indicators were based on OECD (OECD, 2013) and IMF 
forecasts (IMF, 2014b).  Two different forecast models were produced for the 
cases of total health expenditure and total pharmaceutical expenditure: 
according to the ‘optimistic’ model the future likely increase in health care 
spending would be moderate and would be contained to the cumulative 
aggregate average growth rate (CAAGR) of the 2000-2010 period, whereas in the 
‘pessimistic’ model, the increase would be significantly higher and similar to the 
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CAAGR of the 1990-2010 period. Both models assume that no additional 
constraints will be put in place over the period from 2013-2020 relative to what 
the situation was until 2012. The two models were benchmarked against the 
baseline (control) case of zero annual growth in real health spending. In this case, 
the key assumption made about governments’ reaction to current and future 
macroeconomic and other constraints was that future budgets for health care 
were anticipated to remain fixed in real terms; for practical reasons it was 
assumed that health spending in the study countries plateaued in 2012. 
Consequently, the difference between the future demand for healthcare (i.e. 
proxied by forecasted total health expenditure) and the future available 
healthcare resources (i.e. based on 2012 total real health expenditure) was used 
to quantify the possible future gap in available resources. Section 4 presents the 
discussion and forecasts on the above. 
Finally, in addressing the third objective of the paper and in light of the evidence 
presented in sections 3 and 4, section 5 discusses whether health care systems 
are financially sustainable over the longer term and what options are available in 
order to improve their financial sustainability. 
3. FACTORS INFLUENCING THE DIRECTION OF HEALTH 
EXPENDITURE 
3.1 DEMOGRAPHIC CHANGES 
In the 50 years from 1950 to the turn of the millennium, the world population 
aged at a relatively benign rate with the proportion aged 60 and above rising 
from 8% to 10%. In the 50 years from 2000 to 2050, this proportion is projected 
to rise to 22%. By 2030, half the population of Western Europe is expected to be 
aged 50 years or older and have a life expectancy of around 90 years; the rising 
life expectancy also means the proportion of very old citizens, aged 80 and above, 
is the fastest growing group in the world, with an anticipated growth rate of 
more than 3% per year until at least 2020 (Harper, 2010). At the same time, 
younger generations are unable to replenish the economically active population 
at the same rate as older generations retire, leading to a significant decrease in 
the ratio of working- to non-working age population (old-age support ratio) 
(Harper, 2010, DG-ECFIN and AWG, 2009). 
 
3.2 THE NEED FOR PUBLIC PENSION REFORM 
With a rapidly ageing population and longer life expectancies on the horizon, 
there has been considerable interest in the reform of public expenditure on older 
people, such as pensions and health care. In the absence of attenuating policies in 
the European Union (EU), age-related spending – particularly pensions, health, 
and long-term care - on average is projected to account for an additional 27.85% 
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of GDP by 2060 (from 23.1% in 2007), with about half on pensions and half on 
health and long-term care (LTC) (DG-ECFIN and AWG, 2009). Factoring in 
current developments in pension reforms, however, the budgetary impact of 
ageing is reduced considerably in most countries. Based on age structure alone, 
German pensions would rise from 10.3% of GDP (2000) to 26.2% of GDP by 
2050 in the absence of reforms, whereas the figure drops to 13.1% of GDP by 
2050 when reforms are factored in, with a similar trend over a sample of 18 
other OECD countries  (Meier and Werding, 2010).  
Pension spending relies mainly on the population structure and the level of 
benefit per capita; as a result, policy instruments to control spending are largely 
focused on the latter, including linking benefits to lifelong contributions 
(actuarial fairness) and introducing “notional defined contribution” schemes. 
The key issue in most OECD countries is the declining old age support ratio, 
meaning less potential transfers between the economically active and inactive 
population. As the major asset in pay-as-you-go schemes is the human (working) 
capital, a decline in this source of funds means either a decline in benefits per 
capita or a shift to funded pensions, i.e. based on real, accumulated capital (Meier 
and Werding, 2010).   
 
3.3 AGE RELATED HEALTH  
The complexity of healthcare poses a challenge in identifying the main cost 
drivers, which are broadly thought to relate to population ageing and 
technological developments, but there is diverging evidence on the role of ageing 
in particular. Life years gained through increased life expectancy can be spent in 
good or bad health depending on the relative improvements in morbidity and 
mortality: if mortality improves faster than morbidity there is an “expansion of 
morbidity” due to gains in life spent in ill health (Olshansky et al., 1991), whereas 
the opposite scenario gives a “compression of morbidity” (Fries, 1980), or the 
two may balance each other out and postpone morbidity to the end of life. 
In a review of 12 OECD countries, old-age disability was found to be reduced in 
only 5, increased in 3, unchanged in 2 and inconclusive in two countries 
(Lafortune and Balestat, 2007) showing mixed support for the hypotheses of 
expanded/compressed morbidity. However, others have found that most 
measures of morbidity have declined in recent years despite higher incidence of 
chronic diseases, and with morbidity declining faster than mortality this 
supports the compression hypothesis (reviewed in Payne et al., 2007) and 
suggests more moderate future LTC cost. 
Two lines of thought have emerged in quantifying the impact of ageing on 
healthcare expenditure, with some arguing that age itself is a major cost driver 
(Longman, 1987), and others that associations between ageing and spending are 
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explained by omitted variables such as per capita income (eg. Getzen, 1992). 
More recent analyses suggest age impacts spending differently in different 
countries (O'Connell, 1996, Cottarelli, 2010a). Recent studies addressing the 
issue of ageing and cost at patient level have found a stronger correlation 
between spending and proximity to death than age in general (eg. Dixon et al., 
2004), but even in countries were the compression of morbidity theory seems to 
hold, health expenditures have not been seen to decline. Rather, the cost of end-
of-life treatment has stagnated while the costs further from death seem to have 
increased (Payne et al., 2007).  
 
3.4 SHIFT TO LONG-TERM CARE AND OTHER PRIORITIES 
In absolute terms, future demand for healthcare is expected to rise on account of 
the increasing proportion of elderly population, due to the concentration of 
health care expenditure in the later years of life (DG-ECFIN and AWG, 2009, 
Harper, 2010). Moreover, preventable deaths caused by infectious diseases and 
other treatable conditions are declining in most industrialised countries (Nolte 
and McKee, 2008) and chronic conditions are on the rise (Stuckler, 2008). 
Though preventable deaths are declining, a significant proportion of mortality 
(on average 24% of deaths under the age of 75 across 16 high-income countries) 
is still caused by conditions that are treatable (Nolte and McKee, 2011). As health 
systems improve, more survivors may also exert upward cost pressure, in 
particular in the presence of disabilities resulting from illness. 
If the “expansion of morbidity” hypothesis is borne out in reality, which may be 
the case for at least some chronic diseases including dementia and cancer (DG-
ECFIN and AWG, 2009), expenditure on LTC can be expected to rise significantly 
(Fernandez and Forder, 2010). The market for private LTC insurance is limited 
due to difficulties in predicting LTC costs and, by extension, premium setting, as 
well as a number of market failures including information asymmetry and 
adverse selection (Sloan and Norton, 1997, Brown and Finkelstein, 2007), and as 
such the LTC burden is likely to fall on governments and SHI funds. In 
anticipation of this several countries in the OECD area (Japan, Germany and 
Austria, among others) have taken steps to reform their SHI schemes to include 
LTC, while other countries (e.g. France and Spain) have implemented tax-based 
measures (Fernandez and Forder, 2010).  
Although some uncertainty surrounds the impact of ageing and technology on 
health spending, there is less controversy over the impact of diminishing 
productive populations. The proportion of retired (age 65+) to working 
population (age 15-64) is set to rise above 70% in Italy, Spain and Japan by 2050 
(Harper, 2010), and on average in the EU to double from 25.4% in 2008 to 53.5% 
in 2060 (DG-ECFIN and AWG, 2009). This has considerable consequences for 
revenue generation based on economic activity, such as payroll taxes, but also a 
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more subtle effect in reducing the potential work force for informal LTC, which is 
estimated to exceed by several times the value of services provided by formal 
care (Wanless, 2006, Andersson et al., 2003), a situation which is exacerbated by 
increasing female participation in the workforce, increased divorce rates and 
reduced cohabitation across generations (Fernandez and Forder, 2010). As the 
proportion of elderly relying on cheaper informal care is estimated at 80-90%, 
and those relying on institutional care at only 1-12%, a decrease in the 
availability of informal care could have consequences for future LTC costs 
(Saltman et al., 2006).  
 
3.5 PROFESSIONAL INCOME LEVELS, EFFICIENCY, PRICES AND 
TECHNOLOGICAL ADVANCES  
In contrast to other goods and services, the level of healthcare provided and 
consumed is not necessarily driven in its entirety by population demand, i.e. 
health status. Since this question was first addressed in the context of national 
health systems, income level has surfaced as a recurring theme, with higher 
income countries generally spending more on health than lower income (Abel-
Smith, 1967, Gerdtham et al., 1992). Because individual health spending at the 
same time is considered to be relatively inelastic (Manning et al., 1987), this has 
led to the classification by some of health care as an “individual necessity and 
national luxury” and, perhaps detrimentally, to the perception that national 
income matters more than systems of service delivery (Newhouse, 1977). This 
view is countered more recently by work suggesting that GDP measured in 
currency fails to take into account the element of purchasing power, and when 
regressions are based on purchasing power parities (PPP) rather than currency, 
the elasticity of income becomes less than unity, in line with health care as a 
necessity good (Parkin et al., 1987). Consequentially, income as an explanatory 
factor for healthcare expenditure growth should be interpreted with some 
caution.  
A significant body of evidence from high income countries suggests 
developments in medical technology, increases in unit prices of care relative to 
other goods and services, increases in demand for and utilisation of care, 
provider efficiency and a range of other factors are considerably more important 
determinants of health care expenditure than age per se (reviewed in Cremer et 
al., 2007).  
One such factor is physician and other health professionals’ income. Because 
health care is labour intensive, wages of physicians and other health staff have 
the potential to impact expenditure. Comparing Canada and the USA, it was 
found that per capita expenditure on physicians was 72% higher while 
utilisation was actually 28% lower in the USA. Apart from wage differentials, 
significant transaction costs in billing multiple insurers, insuring against 
  12 
malpractice suits and other reasons are suggested for higher costs in the USA 
(Fuchs and Hahn, 1990). 
The role of technology in health care expenditure growth has attracted 
significant attention over the years. Early work using regression modelling 
showed growth between 1947-1967 was mainly attributable to rising prices 
(3.7%), growing income per capita (2.3%) and population growth (1.6%). 
However, 0.6% of growth remained unaccounted for, and was argued to be 
caused by the use of the most advanced technologies available for treating 
patients; this was the so-called “residual approach” (Fuchs, 1972). With a 
negative residual, it was subsequently argued that technological developments 
could also be responsible for decreasing costs by introducing technologies that 
are more efficient (Mushkin and Landefeld, 1979). In a related approach, the so-
called “excess inflation”, the effects of inflation in the wider economy and above-
average inflation of healthcare staff in particular are accounted for, and any 
residual expenditure growth is deemed to be growth in quality and quantity of 
services, much of which is assumed to be technological development (Altman 
and Wallack, 1977).  
Attempts to quantify the contribution of technology more directly have 
employed a “cost of treatment” approach, showing that earlier expenditure 
growth was driven by intensified use of relatively low-cost technology such as X-
rays and laboratory tests (Scitovsky and McCall, 1975), while more recent 
growth was better explained by introduction of new and expensive “big-ticket” 
technologies (Scitovsky, 1985). A related concept is that of “service intensity”, a 
line of thought suggesting that expenditure growth may also be caused by a 
higher volume of services provided to each patient on admission (Newhouse, 
1993).  
Returning to the macro perspective, a cross-section study of 19 OECD countries 
found that apart from income growth, several institutional and structural factors 
affected healthcare expenditure: urbanisation, proportion of public financing, 
proportion of inpatient expenditure and fee-for-service remuneration in the 
outpatient sector. Hospital care and fee-for-service payments increase costs, 
while perhaps surprisingly public financing predicts lower expenditure 
(Gerdtham et al., 1992). Broadly consistent results have been reported, with 
hospital care associated with higher expenditure, and a primary care 
gatekeeping system consistently associated with lower costs probably due to 
lower in-patient expenditure. This study also found a larger stock of physicians 
to be associated with lower expenditure (except when the reimbursement 
system was based on fee-for-service) and a cost-decreasing effect of capitation or 
wages in physician reimbursement.  As a proxy for technological spending, the 
rate of renal dialysis was associated with significantly higher inpatient costs, 
while no significant effects were seen from age structure, female labour force 
participation or unemployment (Oxley and MacFarlan, 1994, annex). 
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Technological advances have extended the range of conditions that can be 
treated, either by curing the disease or extending life and relieving symptoms, 
while the scope of diagnostics has been increased considerably by e.g. imaging 
technologies (Oxley and MacFarlan, 1994). Some newer treatments such as 
organ transplants or kidney dialysis bear extremely high price tags and the 
dissemination of such technologies together with universal coverage means the 
expected health care cost per individual trends upwards (Weisbrod, 1991). 
However, as noted above, the magnitude of the effect of technology on total 
expenditure alongside other supply- and demand side factors remains a question 
of significant debate.  
As a result of the continuous growth in healthcare expenditure, most OECD 
governments have introduced cost containment measures; these have included, 
among others, wage and price controls, resulting in relative stability of 
expenditures until the 1990s (Docteur and Oxley, 2003), but also and more 
extensively, budget setting and budget-shifting practices (Stabile  et al., 2013).  
For example, reforms to ensure sustainability in social health insurance (SHI) 
systems have included linking the growth in overall SHI revenues to the rate of 
increase in salaries (Germany), enacting additional out-of-pocket payments 
(Netherlands), removing expensive, non-essential drugs from the publicly 
reimbursed package (France) and introducing an index to limit expenditure 
growth (Belgium) (Saltman, 2004), however such reforms may compromise 
access, equity or other core values, and are generally aimed at achieving short 
term cost control. 
An analysis of OECD public health expenditure from 1981 to 2002 revealed an 
average growth of 3.6% per year, of which only 0.3% was accounted for by 
demographic effects. The majority (2.3%) was due to income (assuming unity 
income elasticity of health care), while a residual of 1% was argued to be largely 
due to technological advances. By 2050, demographics have been projected to 
increase average OECD health spending by only 0.6% of GDP (5.7% to 6.3%), 
while a “business as usual” scenario where spending grows at historic rates 
would almost double expenditure to 9.6%. Reducing the 1% residual by e.g. 
controlling uptake of new technologies predicted a lower expenditure growth to 
7.7% of GDP by 2050 (Martins and De la Maisonneuve, 2006). Similarly, an 
analysis of 1970-2002 per capita healthcare expenditures in OECD suggested 89% 
of growth was due to increased benefit levels, including the uptake of new 
treatments, while the remaining 11% would be attributed to demographic 
factors (Hagist and Kotlikoff, 2005). 
 
4. CURRENT TRENDS AND FUTURE PROJECTIONS IN KEY 
VARIABLES INFLUENCING HEALTH CARE EXPENDITURE  
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It has already become clear that numerous factors influence health spending or 
individual elements of health spending (e.g. in-patient care, pharmaceutical care, 
long-term care). Such factors may not be related – strictly speaking – to the 
health care system and, as a result, are exogenous to it, whereas others may stem 
from it and, consequently, as endogenous. More specifically, exogenous factors 
act independently of the healthcare system but may still have a major influence 
on system performance and sustainability, and include overall macroeconomic 
performance and investment in broader social policy such as public pensions. 
Endogenous factors are inherent in healthcare systems where they directly 
influence expenditure; these include the impact of technological and 
demographic developments.  
 
4.1 TRENDS AND PROJECTIONS IN EXOGENOUS FACTORS POTENTIALLY 
INFLUENCING HEALTH EXPENDITURE 
Macroeconomic Performance  
Using real GDP growth as a metric, it can be seen that the long-term performance 
of the eight study countries has declined over the past 30 years. Although real 
annual GDP growth since 1970 has had several peaks and troughs, in the long 
run there is a clear downward trend for all countries except Poland. In 1972-
1973 most countries reached the peak of their GDP growth rates of around 7-8% 
(Australia outperformed with 11% and Germany underperformed with 5%), 
whereas by 2008-2009 most countries reached their lowest point of around -2% 
to -5% (with the exception of Poland, which maintained positive growth).  
Real average GDP growth rates are declining over time.  Looking at 20 year 
average annual growth rates for each country, values for 1971-1990 ranged from 
2.2% (UK) to 3.2% (Canada) with the average of 7 countries being equal to 2.8% 
(Poland not included due to missing data); values for 1991-2010 range from 0.8% 
(Italy) to 3.3% (Australia), with the average of the 7 countries equal to 1.95% 
(Poland has the highest average of 3.8% and is excluded for comparability). 
Between the 7 countries, only Australia has a higher average annual growth rate 
in the latter period, rising from 2.58% to 3.29% (+0.7%). All other countries 
experience a decline ranging from -2.17 (IT) to -0.18 (UK) %. 
General government debt has been rising at an almost constant rate. An 
examination of 10-year intervals since 1990 suggests that gross debt as % of 
GDP has risen for all countries, on average from 49.3% in 1990, to 58.1% in 2000, 
then to 72.8% in 2010 and, most recently, rising to 82.9% in 2014 (Figure 1). In 
2014, Italy had the highest debt figure among the 8 study countries (134.5% of 
GDP), while Australia had the lowest at 30.8%, followed by Poland at 49.5% 
(Table 2). The overall trend for net debt (gross debt of the general government 
minus its financial assets in the form of debt instruments) over the period is also 
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increasing, on average from 38.0% in 1990, to 41.2% in 2000, to 49.2% in 2010 
to 60.3% in 2014 (Figure 1). Australia, Canada and Poland are notable exceptions 
to this trend, despite an upturn in 2014, total net debt remains below the 8-
country average at 16.1%, 39.5% and 21.8% in 2014 respectively; whereas Italy 
again had the highest debt at 112.4% followed by France at 89.5% (Table 2). 
Fiscal deficits have also been increasing, especially during the last decade, where 
the 8 country average deficit as % of GDP has risen from 0.4% in 2000 to 6.6% in 
2010 and fallen slightly to 3.4% in 2014 (Figure 1); with fiscal deficits reflecting 
the increase in average gross debt and net debt over the same period (Table 2).  
These developments have a number of consequences for future levels of health 
spending. First, declining GDP growth in isolation reflects a slowing of economic 
activity and consequently lower growth in public revenues from personal income 
and corporate taxes to support rising demand on health and, ultimately, health 
spending. Second, increases in overall government debt levels lead to higher 
levels of debt repayment in the future as a percent of GDP. Third, excessive fiscal 
deficits as a percent of GDP require tighter fiscal policies in order for these to be 
reduced and for the budget to be balanced. In the opposite case, excessive 
borrowing is only going to lead to a deteriorating debt position; this is neither 
politically acceptable nor financially sustainable. In combination with increasing 
public debt over the past decades, and the current focus on reduction of fiscal 
deficits to improve this situation, this is likely to result in lower public 
expenditure on aggregate, including in the health sector.  
In sum, higher re-payments due to higher debt levels imply fewer resources 
available for health; some countries are protecting or ringfencing the level of 
public spend devoted to health, but this is at best taking place at nominal, rather 
than real, level and does not take into account the year-on-year increase in the 
demand for health care due to ageing and related factors.  The need for tight 
fiscal policies over the longer term implies that governments will very 
reluctantly agree to real increases in public (and health) spending. This trend 
will intensify in a situation where GDP growth remains low. 
 
Public spending by sector and the impact of pension financing 
The single largest category of public expenditure across all countries is social 
protection, accounting for approximately 32-54% of total public spending 
(Figure 2). It includes public pensions and other cash- and kind benefits such as 
housing, child and disability benefits. In general, public pensions constitute a 
significant cost pressure for public finances and spending as a proportion of GDP 
has been increasing since 1980 (Figure 3); the exceptions in our study countries 
are Canada, Australia and the UK, where, except for basic or state pensions, much 
of the burden has been shifted from the public sector to individual households,  
with the latter making their own arrangements through private pension 
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providers. Expenditure on public pensions as a percent of GDP ranged from 2.8% 
(Canada) to 9.7% (Germany) in 1980, while in 2011 the range was 4% (Canada) 
to 13.5% (Italy). Italy and France experienced the highest burdens of 13.5% and 
12.5% respectively, whereas Germany was the only country with a decrease in 
public spending over time (-11.3%) (Figure 3). 
A more detailed view of social protection trends suggests that in most countries 
(except Poland and the UK) social protection spending has remained relatively 
stable or increased slightly in the past decade (Figure 4).  
 
4.2 TRENDS AND PROJECTIONS IN ENDOGENOUS FACTORS INFLUENCING 
HEALTH EXPENDITURE 
Demographic structure and the dependency ratio  
Developments in demographics are likely to increase the demand for health care 
in a variety of ways as discussed earlier.  A trend of increasing life expectancy at 
65 years is seen in all countries since 1970 (except for Poland in 1970-1990). 
Figure 5 shows the increase in male life expectancy between 1960 and its 
projected value in 2020. The 8-country average has shifted from 12.4 years in 
1970 to 17.5 years in 2009, an increase of 5 years (40.6%). Based on linear 
regression, projections for 2020 indicate a male life expectancy at 65 of 19.9 
years, an increase of 2.5 years or 13.9% higher than in 2009. 
Longer life expectancy is expected to lead to a higher proportion of elderly in the 
population (Figure 6).  The 8-country average proportion of population over 65 
has increased from 10.5% in 1970 to 16.5% in 2010, a 54.5% increase. At one 
end of the spectrum Australia, Canada and Poland represent relatively ‘young’ 
populations with their over-65 populations amounting to 13.3%, 13.9%, and 
13.5%, respectively in 2010. On the opposite end, Germany and Italy represent 
the relatively ‘old’ populations where share of the over-65s has reached 20.5% 
and 20.2% of the total respectively, in 2010.  In France, Spain and the UK the 
share of the over-65s in the population amounted to 16.7%, 16.7% and 15.8%, 
respectively in 2010. Projections suggest that the 8 country average share of 
over-65s in the total population could grow from 16.5% in 2010 to 18.1% in 
2020, assuming fertility rates and other factors influencing demographics remain 
unaffected. 
The combined increase in life expectancy and the share of the over-65s in the 
population has a direct effect on the old age dependency ratio, defined as the 
number of people at working age to the number of people over 65. Since 1960, 
the 8 country average ratio has dropped from 6.3 working persons per non-
working person to 3.8 in 2010, almost a 40% decline (Figure 7). In 2010, 
Germany and Italy had an old age dependency ratio of 2.9 and 3.0, respectively, 
whereas in Australia, Canada, and Poland this ranged between 4.4 and 4.8. 
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Projections for 2020 show the 8 country average ratio decreasing to 3.0, with 
Germany’s and Italy’s declining to 2.6.  
 
Pharmaceutical Spending  
To illustrate the impact of technological developments on health spending, 
pharmaceutical expenditure was used as a proxy. Total pharmaceutical spending 
increased significantly in real terms between 1990 and 2010 (Figure 8). 
Specifically, the cumulative 20 year increase ranged from 24% in Italy (from 
€11.6bn to €14.4bn) to 303% in Australia (AU$3.0bn to AU$12.0bn or €1.6bn to 
€8.4bn), with a 7 country average (Poland excluded due to missing data) of 
130%. In real absolute terms, Canada had the highest increase in real 
pharmaceutical expenditure, whereas Italy had the lowest. 
In terms of likely future trends, the projected total real expenditure for 2020 as a 
percentage change of 2012 under the two scenarios we have used to calculate 
projections is shown in Figure 9. The average change for all 8 countries ranged 
from 13.0% according to our optimistic scenario of moderate cost increase to 
26.2% according to our pessimistic scenario of significant cost increase.  The 
baseline (median) value stood at 19.6%.  
 
4.3 HEALTH EXPENDITURE TRENDS AND PROJECTIONS  
Having examined endogenous cost drivers (demographics, medical technology) 
and exogenous financial pressures (macroeconomics, public pensions) on health 
systems, it has been shown that health expenditure growth has outpaced GDP 
growth over the course of the past 20 years.  Figure 10 summarises the growth 
rates in the study countries and shows that the 10-year increase between 1990 
and 2000 in national currency ranged from 20.3% in Italy (€54bn to €65bn) to 
149.1% in Poland (ZL3.0bn to ZL7.4bn or from €0.7bn to €1.9bn); the average 
increase across the 8 study countries was 53.3%. Between 2000 and 2010, the 
change in the rate of expenditure growth ranged from -6.8% in Germany (from 
€180.5bn to €168.2bn) to 87.1% in Poland (ZL7.4bn to ZL13.8bn or from €1.9bn 
to €3.4bn), with the average increase being 45.1%. For the entire 1990-2010 
period the 20-year cumulative increase in real health spending ranged from 49% 
in Italy (from €54bn to €80.6bn) to 366% in Poland (ZL3.0bn to ZL13.8bn or 
from €0.7bn to €3.4bn), the average for all 8 countries being 139%. In real 
absolute monetary terms, France has had the highest rise in expenditure, an 
increase of €5.6bn, whereas Poland has the lowest, an increase of ZL10.8 billion 
(€2.6bn) (Figure 10). 
The projected total real health expenditure for 2020 as a percentage change of 
2012 values under the two scenarios (‘optimistic’ and ‘pessimistic’) is shown in 
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Figure 11. The average change for all 8 countries ranges from 20.8% (optimistic) 
to 28% (pessimistic) with a median value of 24.4%.  
Based on the assumption that countries are going to resist real increases in 
health spending in the future because of adverse fiscal and other macroeconomic 
conditions, we are able to calculate the extent of future funding gaps. This is done 
by using the projected total real health expenditure values, which act as a proxy 
for health care demand, and subtracting from these the real health spending 
values assuming zero health spending growth for the next 8 years (2012 – 2020). 
The funding gaps, therefore, illustrate the difference between the projected 
future levels of demand for health (trend of total health spending) and a 
hypothetical zero growth in health care budgets in real terms at 2012 levels. 
Based on this, Figure 12, shows the funding gap for the 2012-2020 period for the 
case of Canada; the gap (vertical line) is quantified as the difference between the 
2012 real total health expenditure (horizontal dashed line) and the forecasted 
demand for healthcare under two scenarios. The potential gap in 2017 is shown 
to range from CN$ 17.3bn (€ 11.4bn), based on the optimistic scenario to 
CN$ 21.9bn (€ 14.5bn) based on the pessimistic scenario. These values 
correspond to 13.7% and 17.4% of 2012 Canadian total health expenditure 
respectively, with a baseline (median) a gap of CN$ 19.6 billion (€ 15.7bn) or a 
15.6% increase based on 2012 value.   
The minimum and maximum ranges of funding gaps, reflecting the optimistic 
and pessimistic scenarios respectively, have been calculated for the remainder of 
the study countries for 2017 relative to 2012. These are as follows: Australia 
AU$12.0bn or € 8.0bn (15.6% of real total health spending in 2012), France 
€19.0bn (11.4%), Germany -€3.1bn (-1.9%), Italy €11.5bn (15.0%), Poland 
€3.5bn (24.2%), Spain €10.0bn (19.5%), and United Kingdom £11.3bn or € 
15.3bn (15.0%). The mean magnitude of the funding gap for 2017 across the 8 
countries for each scenario is 12.3% (optimistic scenario), and 17.7% 
(pessimistic scenario) of 2012 total real health expenditure, respectively. 
With respect to the baseline, the cumulative funding gaps in 2017 and their 
respective percentage changes based on 2012 real health expenditure are as 
follows: Australia AU$ 36.0bn or € 24.1bn (46.8%), Canada CN$ 60.3bn or € 
39.9bn  (47.9%), France  € 62.8bn (37.8%), Germany  -€5.8bn (-3.6%), Italy  
€45bn (58.3%), Poland  €11.1bn  (76.8%), Spain  €32.9bn (64.2%), and United 
Kingdom £62.9bn or € 85.4bn (73.3%), as illustrated in Figure 13. The mean 
magnitude of the cumulative funding gap across the 8 countries for each scenario 
is 39.4% (optimistic scenario), and 61.0% (pessimistic scenario) of 2012 total 
real health expenditure. 
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5. IS HEALTH CARE FUNDING SUSTAINABLE OVER THE 
LONG-TERM? 
The data presented in the previous section show a declining overall GDP growth 
across the past three to four decades in 7 of the 8 countries studied (Poland 
being the exception), and a constantly increasing (although at a declining rate) 
level of healthcare expenditure. As discussed above, real total health spending 
for all countries has been rising at high rates. Between 1990 and 2010, the 
average increase in total real health expenditure in the 8 countries was 139%, 
ranging from 49% in Italy to 366% in Poland.  In contrast, spending on pensions 
has stabilized and in some cases declined in the 2000s despite a monotonously 
increasing life expectancy and proportion of elderly population, due to various 
policy initiatives implemented to control growth (Meier and Werding, 2010), 
partly shifting the burden to households. 
Total health expenditure growth has slowed down over the past few years across 
all study countries. Reforms to stabilise the rate of growth of health expenditures 
have seen a mix of supply and demand side measures to promote cost 
containment and macroeconomic efficiency. In this context, measures have 
included cutting minor benefits, increasing user charges, encouraging GP 
gatekeeping, introducing prospective hospital reimbursement through DRG 
implementation, pharmaceutical price controls, broader use of health technology 
assessment (HTA), budget caps on hospitals and GP practices, restrictions on GP 
pay rises and pharmaceutical benefits, and embarking on decentralization 
(Cottarelli, 2010a, Cottarelli, 2010b). 
While estimates of the impact of ageing on health expenditure differ, some 
upward pressure is inevitable. It has been estimated that in some countries 
(including Italy and Germany), ageing is the only cost driver for the next two 
decades and will result in an increase of less than 1% of GDP, whereas in others, 
ageing only constitutes around 30-50% of a projected increase of 1-2% of GDP 
(including Australia, Canada, France and Spain). In extreme cases, including the 
UK and the US, the non-age related cost growth alone could reach 3% of GDP in 
the next 20 years due to rising incomes, technological advances, the Baumol 
effect (increase in wages without associated increase in productivity) and health 
policies/institutions.  
Pharmaceutical spending, which is used as a proxy for the impact of medical 
technology, is shown to be increasing moderately or significantly. Overall, over 
the 1990-2010 period all countries experienced a major growth in real 
pharmaceutical spending ranging from 23.9% in Italy, to 303.1% in Australia, 
with the 8-country average being 130.4%. The slowing of pharmaceutical 
expenditure growth since 2000 coincides with the establishment of national 
authorities to review clinical and cost-effectiveness of new pharmaceutical 
interventions before admission into national reimbursement lists, including the 
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UK National Institute for Health and Care Excellence (NICE) in 1999 and the 
Institute for Quality and Efficiency in Health Care (IQWiG) in Germany in 2004, 
and also with the expiry of patents on certain blockbuster drugs and increased 
use of generics (Aitken et al., 2009). Health Technology Assessment (HTA) 
agencies such as NICE and IQWiG determine which new technologies constitute 
value for money, but the question of which existing technologies are ineffective 
or even unsafe is not yet part of the agenda (Elshaug et al., 2009, Kanavos et al., 
2009) e.g. due to resource limitations and lack of a clear methodology for 
disinvestment. Disinvestment in particular can be difficult to implement without 
considerable stakeholder resistance (Elshaug et al., 2009, Elshaug et al., 2008). 
While policies to curb pharmaceutical expenditure are implemented across the 
study countries and more widely within the entire OECD area, these are unlikely 
to have much long term impact given the proportion of pharmaceuticals to total 
health spending is approximately 15% in most OECD countries (Cottarelli, 
2010a).  
Sustainability of health system financing is not an entirely new area of concern 
and enquiry, but an issue that has been raised across several decades. For 
example, in the early 1980s, there was concern over the rising costs of Medicare 
in the USA caused by an ageing population which, in turn, would mean less 
productive population and higher utilisation of health services (Fuchs, 1984). 
Recent evidence from a cross-section of Australian physicians and health service 
consumers (general population) suggests the issue of sustainability is familiar to 
the majority of the population, with elderly respondents more likely to be very 
concerned about cost of care. Doctors seem to be more concerned with the cost 
of technological innovations than patients, and a large majority (82.9%) of 
consumers vs approximately one third of doctors feel treatments should be 
offered no matter how small the chance of benefit and how high the cost 
(Robertson et al., 2011), highlighting the inherent difficulty in rationing medical 
treatments. Today the concern has been generalised across many –if not most- 
OECD countries and materialised into a bona fide sustainability threat. As a result, 
policy-makers are faced with the need for significant short- and long-term 
savings.  
However, long-term savings are unlikely to materialise from indirect and direct 
price cuts and controls alone, but, rather more likely from increasing the 
efficiency and modernising the delivery of health care services. Indeed, a number 
of sources of inefficiency have been identified in areas such as pharmaceutical 
utilisation, health care goods and services, labour inputs to the health care 
system, and health care interventions that, if addressed, could provide both 
savings and efficiency gains for the future (Chisholm and Evans, 2010). More 
specifically, these include, among others, the underuse of generic 
pharmaceuticals in many settings and the higher than necessary prices for 
medicines; the inappropriate (overuse, underuse, misuse) and ineffective use of 
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prescription pharmaceuticals; the overuse or over-supply of equipment, 
investigations and procedures; the inappropriate or costly staff mix and 
associated incentive structures leading to potentially unmotivated health 
workforce; and potentially inappropriate hospital admissions and length of stay 
(Chisholm and Evans, 2010). The above should also be supplemented by factors 
such as medical errors, the provision of low quality of care, but also wasteful use 
of resources, corruption and fraud, which remain hidden agenda items in most 
health care systems. 
Since most countries face escalating fiscal pressures, we assume there will be a 
turning point on the growth of their health care budgets. By taking 2010 as the 
year of this turning point, we assume that healthcare spending in real terms will 
remain constant during the following years. In using as a proxy for demand for 
healthcare the temporal trend of (observed and projected) health expenditure, 
we observe a gap between future demand and supply. The average forecasted 
funding gap for 2017 across the 8 countries has a baseline value of 15.0%, 
ranging from the ‘optimistic’ value of 12.3% to the ‘pessimistic’ value of 17.8% of 
2012 total health spending.  
Options to address the problem of the escalating expenditure for health care and 
the resulting funding gap(s) can be divided into three main categories. The first 
category relates to increasing the level of resources available for health care; this 
could be achieved in a number of ways, for example by increasing taxes and/or 
social insurance contributions, or reallocating budgets from other areas of 
government spending into health care. The public acceptability of different tax 
increases may vary according to setting; typically, “sin” taxes e.g. on tobacco, 
alcohol or other unhealthy consumption goods, such as the tax on saturated fat 
recently introduced in Denmark (Folketinget, 2011), carry a greater degree of 
acceptability than do increases in income tax or taxes on general consumption.  
However, the fiscal benefit of those taxes that are considered to be ‘acceptable’ 
from a societal perspective is likely to be limited. An additional downside is that 
some of these taxes may be regressive and may not necessarily tackle the reason 
why some consumers are more likely to engage in risky or unhealthy behavior. 
The reallocation of funds from other areas of public spending, such as social 
protection, education or defense, may be politically sensitive, particularly with 
regards to shifting funds from the education budget. Nevertheless, data from 
recent years suggest that social protection spending as a proportion of total 
spending fluctuates from year to year and could be amenable to modest or 
moderate shifts to the health sector. 
The second category is associated with policies to decrease the health system’s 
obligations and its associated costs. This could be achieved through rationing 
non-clinical quality coverage such as waiting times, enabling population/service 
exclusions from coverage, expanding cost-sharing, and enabling a variety of 
supplementary health insurance options. Rationing is likely to be feasible in less 
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essential services, such as dentistry, physiotherapy or optical services, and a 
well-functioning private insurance market would be able to offer such coverage 
on a voluntary basis. A number of countries have already opted for this and 
reduced the level of coverage to their citizens significantly in dental or optical 
care, unless where it is absolutely essential and medically necessary. Excluding 
population groups from some coverage on a means-tested basis is possible and 
already implemented in some instances, e.g. free prescriptions for children, 
disabled and other vulnerable groups in the UK NHS. As cost-sharing has been 
shown to have some negative effect on health service utilization (Manning et al., 
1987), such measures must be implemented with care, but are likely to be 
feasible for less essential services. 
The final category of measures relate to improving the efficiency of the health 
care system and would include reforming service delivery by introducing Health 
Technology Assessment (HTA), prescribing guidelines, changing provider 
payment methods and refining the incentive structure for health professionals, 
and, even, privatising parts of the health care system, increasing competition on 
the delivery of health care or enabling a variety of complementary private 
insurance options. An efficient pharmaceutical policy, which includes generic 
substitution and price controls for originator drugs, may help to control 
spending in this category, as may the use of HTA to limit uptake of technologies 
with limited benefit. Disinvestment in existing procedures and technologies that 
are not cost-effective may become an area of increased focus in the near future. 
The introduction of market mechanisms to increase provider competition and 
efficiency is argued by some to result in savings, though the overall picture on 
this is unclear.  
Overall, in order for health care systems to remain financially sustainable over 
the long-term and for publicly funded health care systems to retain their public 
nature, a number of incisive reforms need to be implemented; first, there needs 
to be intensified focus on an outcomes-based reimbursement system by refining 
the incentive structure for health care professionals and providers; second, there 
is significant need to apply HTA rules to ensure value for money not only based 
on available clinical trial evidence (efficacy) but also in daily clinical practice 
(effectiveness and indeed relative effectiveness); third, it is imperative to further 
negotiate reimbursement rates to ensure technologies, procedures and health 
interventions are not only cost-effective, but also affordable; fourth, it may be 
necessary to adjust the models of payment for services to the benefit they deliver 
to patients or society; for example, tiered payments could be offered for 
interventions that are administered at a discrete point in time – and would 
therefore require a significant amount of investment upfront - but deliver benefit 
over a patient’s lifetime; fifth, it is important to simplify and rationalise 
processes to facilitate organisational innovation, support care integration and 
coordination as well as streamline administration in order to improve health 
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care delivery; sixth,  it is increasingly important to ensure that health 
professional mix is constantly refined to reflect need and severity; greater use of 
nurses, nurse prescribers and practitioners as well as pharmacists would enable 
(senior) clinicians allocate their time more efficiently to more demanding cases;  
seventh, it is critical to develop – if not already available - national health 
information technology frameworks characterised by an overarching data 
interface, which would link insurers with all providers, avoid duplication in 
service provision and improve efficiency in service delivery; eighth, health 
systems need to ensure they make clinical data on interventions, outcomes and 
costs available to researchers in order to monitor performance and evaluate the 
outcome of specific policy interventions; and, finally, it remains essential to 
constantly identify revenue sources to provide comprehensive health insurance 
coverage for everyone, where this is needed.  
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Table 1 
Overview of health system financing mechanisms in 8 OECD countries 
 
Country Health system financing 
(payer) 
Health service 
provision 
Private 
Health 
Insurance 
Australia Public (General taxation + 
health tax) 
Public and 
private 
Voluntary 
Canada Public (general taxation) Public and 
private 
Voluntary 
France Social Health Insurance 
(statutory) and public 
(general + health tax) 
Public and 
private 
Voluntary 
Germany Social Health Insurance 
(statutory) and public 
(general taxation) 
Public and 
private 
Voluntary 
(some 
substitutive) 
Italy Hybrid of Social Health 
Insurance and Public  
Public and 
private 
Voluntary 
(some 
substitutive) 
Poland Public (Health tax + general 
taxation) 
Public and 
private 
Voluntary 
(limited scope) 
Spain Public (General taxation + 
National Insurance) 
Predominantly 
public 
Voluntary 
United Kingdom Public (General taxation) Public and 
private 
Voluntary 
 
Sources: Australia (HiT, 2006); Canada (HiT, 2013); France (HiT, 2015); Germany (HiT, 2014a); 
Italy (HiT, 2014b); Poland (HiT, 2011a); Spain (HiT, 2010); UK (HiT, 2011b). 
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Figure 1 
Eight country average General Government Gross debt, Net debt and Deficit 
as % of GDP, 1990-2014 
 
 
Note: Includes the following countries: UK, Germany, France, Italy, Spain, 
Australia, Canada, Poland. 
Source: IMF, World Economic Outlook Database, April 2014. 
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Table 2 
General Government Gross debt, Net debt and Deficit as % of GDP, 1990 - 2014 
 
  Gross debt (% of GDP) Net debt (% of GDP) Deficit (% of GDP) 
  
1990 2000 2010 2014 1990 2000 2010 2014 1990 2000 2010 2014 
Australia 16.4 19.5 20.5 30.8 9.6 7.1 3.9 16.1 0.29 1.74 -5.08 -3.36 
Canada 75.2 82.1 83.1 87.4 43.7 46.2 29.7 39.5 -5.65 2.94 -4.93 -2.50 
France 35.2 57.4 82.4 95.8 25.4 51.4 76.1 89.5 -2.48 -1.52 -7.09 -3.68 
Germany n/a 60.2 82.5 74.6 n/a 40.6 58.2 52.9 n/a 1.14 -4.15 0.02 
Italy 94.3 108.6 119.3 134.5 89.2 93.2 100.0 112.4 -11.40 -0.91 -4.38 -2.69 
Poland n/a 36.8 54.8 49.5 n/a 6.9 20.5 21.8 n/a -3.03 -7.86 -3.54 
Spain 42.5 59.4 61.7 98.8 30.3 50.4 33.2 65.7 -3.52 -0.95 -9.61 -5.89 
UK 32.4 40.5 78.5 91.5 29.9 33.9 72.2 84.4 -1.54 3.55 -9.97 -5.28 
Average 49.3 58.1 72.8 82.9 38.0 41.2 49.2 60.3 -4.05 0.37 -6.63 -3.37 
 
Source: IMF, World Economic Outlook Database. 
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Figure 2 
Public spending by sector and type of activity 
 
 
 
Source: OECD Statistics Database, 2014. 
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Figure 3 
Public Pensions as % of GDP 1980-2011 
 
 
 
 
 
Note: Includes the following countries: UK, Germany, France, Italy, Spain, 
Australia, Canada, Poland. 
Source: OECD Statistics Database, 2014. 
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Figure 4  
Social protection as proportion of total public spending over time 
 
 
 
Source: OECD Statistics Database, 2014. 
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Figure 5 
Male life expectancy at 65 years, 1960-2020 
 
 
 
 
 
Note: 12020 figures are based on OECD projections. 
Source: OECD Statistics Database, 2014. 
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Figure 6 
Elderly population over 65, 1960-2020 
 
 
 
 
 
Note: 12020 figures are based on OECD projections. 
Source: OECD Statistics Database, 2014. 
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Figure 7 
Eight OECD country average, lower limit and upper limit on old age 
dependency ratio 1960 – 20201 
 
 
 
 
Note: 12020 figures are based on OECD projections. Upper boundary reflects the 
values from Poland and the lower boundary reflects the values from Italy. 
 
Source:  OECD, Pensions at a Glance 2013. 
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Figure 8 
Total Real Pharmaceutical Expenditure Growth: % change 1990-2000, % 
change 2000-2010, and 1990-2010 change in national currency units (NCU), 
billion 
 
 
 
 
 
Source:  The authors based on OECD and World Bank data. 
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Figure 9 
Total Real Pharmaceutical Expenditure Growth Projection: Percent change 
2012 - 2020 
 
 
 
  
 
Source:  Authors’ projections based on OECD and World Bank data.
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Figure 10 
Total Real Healthcare Expenditure Growth: Percent changes between 
1990-2000 and 2000-2010, and 1990-2010 change in national currency 
units (NCU), in billions 
 
 
 
 
 
 
Source:  The authors based on OECD and World Bank data. 
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Figure 11 
Total Real Health Expenditure Growth Projection: Percent change 2012 - 
2020 
 
 
 
 
Source:  Authors’ projections based on OECD and World Bank data. 
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Figure 12 
Canada’s total real health expenditure 1990-2012, and evolution of 
potential funding gap, 2012-2020  
(in real national currency units at 1990 prices1) 
 
 
 
 
 
Note: 1 The funding gap is calculated based on the assumption that real health 
spend will remain fixed beyond 2012, which is the baseline year.  
 
Source:  Authors’ projections based on OECD and World Bank data. 
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Figure 13 
Cumulative funding gaps across the 8 OECD countries, 2012 - 2017  
(ranges shown as error bars) 
 
 
 
Source:  Authors’ projections based on OECD and World Bank data. 
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